Alphatec Q3 2025 Earnings Report

Alphatec EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.06
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Alphatec Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $182.78 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Alphatec Announcement Details

• Quarter: Q3 2025
• Date: 10/30/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, October 30, 2025
• Conference Call Time: 4:30PM ET

Alphatec (NASDAQ:ATEC) (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market. Alphatec has introduced technologies such as the iGAINS® implant for adjustable anatomical fit and the SONICanchor® fixation system to enhance implant stability. Its proprietary OsteoStrand™ biologic portfolio supports bone growth through versatile carrier options, reflecting the company’s emphasis on combining mechanical and biological approaches to fusion.

Alphatec serves a broad patient base across North America, with expanding footprints in Europe, Latin America and select Asia-Pacific markets. The company collaborates with hospitals, ambulatory surgery centers and specialty spine centers, providing training and support services to surgeons adopting its technologies. Regional distribution agreements and direct sales channels aim to ensure consistent product availability and clinical support worldwide.

Under the leadership of President and Chief Executive Officer William J. Dickerson, Alphatec has pursued strategic partnerships and targeted acquisitions to diversify its technology pipeline. The senior management team brings experience in medical device commercialization, regulatory affairs and global operations. With ongoing investments in research and development, Alphatec continues to advance its next-generation systems and digital planning tools to address evolving surgical needs in spine care.